111’s (YI) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 111 (NASDAQ:YI) in a research report released on Friday,Weiss Ratings reports.

111 Stock Performance

NASDAQ YI opened at $8.66 on Friday. 111 has a fifty-two week low of $4.15 and a fifty-two week high of $15.80. The stock’s fifty day moving average is $6.57 and its two-hundred day moving average is $7.27. The firm has a market capitalization of $74.06 million, a P/E ratio of -2.17 and a beta of 0.46.

Institutional Investors Weigh In On 111

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after purchasing an additional 305,339 shares during the period. Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in shares of 111 during the fourth quarter worth $245,000. Finally, FIL Ltd acquired a new stake in 111 in the 4th quarter valued at about $450,000. Hedge funds and other institutional investors own 21.32% of the company’s stock.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.